Enhancement of anti-lymphoma immuno-effects mediated by dendritic cells pulsed with heat-stressed and rituximab-coated CD20+ lymphoma cells.
Rituximab, a CD20-reactive chimeric monoclonal antibody (mAb), induces apoptosis of lymphoma cells and promotes phagocytosis by dendritic cells and produces a cellular immunoresponse by cross-presentation of tumor antigens to T cells. Heat-stressed tumor cells also stimulate dendritic-cell maturation and induce specific cytotoxic T cells against tumor cells by inducing expression of heat-shock proteins. In this study, we used heat-stressed and rituximab-coated CD20+ lymphoma cells as antigens to load onto immature dendritic cells, and found that rituximab-coated CD20+ Raji cells could promote phagocytosis by dendritic cells, and that rituximab-coated or heat-stressed and then rituximab-coated CD20+ Raji cells resulted in increased dendritic cell maturation. Moreover, only CD20+ Raji cells treated with heat and rituximab effectively enhanced the immunostimulating functions of dendritic cells. Thus, our data indicate that rituximab and heat-shock proteins have synergistic effects, resulting in increased induction of cytotoxic T cells against B-cell lymphoma.
Ai
Limei
L
Department of Hematology, Peking University First Hospital, 100034, Beijing, China.
Ren
Hanyun
H
Department of Hematology, Peking University First Hospital, 100034, Beijing, China. renhy0813@163.com.
Shi
Yongjin
Y
Department of Hematology, Peking University First Hospital, 100034, Beijing, China.
Dong
Yujun
Y
Department of Hematology, Peking University First Hospital, 100034, Beijing, China.
D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D003713:Dendritic Cells / Q000276:immunology*; D006360:Heat-Shock Proteins / Q000276:immunology; D018869:Heat-Shock Response / Q000276:immunology*; D006358:Hot Temperature; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects / Q000276:immunology; D008223:Lymphoma / Q000276:immunology*; D000069283:Rituximab; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D006360:Heat-Shock Proteins; D000069283:Rituximab